• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
learn more
healthcare providers

Iris Buchanan-Perry, MD, MSc, FAAP

Healthcare Provider
Associate Professor
Morehouse School of Medicine
720 Westview Drive
Atlanta, Georgia, United States

Dr. Buchanan serves as a Clinical Instructor in patients with hemoglobinopathies. Dr Buchanan has been involved in clinical research and care of patients with Sickle Cell Disease locally and nationally. Experience in national clinical trials includes Props I, Pre-operative transfusion study and STOP. She has recently submitted a proposal for a national collaboration in the modulating effect of various opioids on the development of the acute chest syndrome in patients with sickle cell disease. Dr. Buchanan has been a member of the NIH Sickle Cell Disease advisory board and is presently a board member of the Sickle Cell Disease Association of America (SCDAA) and the Sickle Cell Foundation of Georgia. Recent training includes a master’s degree in epidemiology. Dr. Buchanan is the Co-Director of the Division of Pediatric Research as well as Director of Research for the MSM pediatric residents, which involves in the training of research principles and study design.

view full profile

expertly curated content related to this topic

Don’t forget to join the oneSCDvoice community!

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close